



CoRISMA Inc. a Delaware C Corp

Mike Theran CEO & Cofounder

Heart Failure: A Global Pandemic




HF Hospitalizations
#1 Leading Cause




American
Heart
Association®

1 in 5 will develop HF

Patients



Costs



Heart Failure: A Progressive and Terminal Disease

TREATMENT OPTIONS

Class 2

Some Physical Limitation
Stents, Rhythm Management

Class 3

Marked Physical Limitation
Therapeutic Gap


CoRISMA Inc Target Market
Class 3 + 4
Advanced Heart Failure (AHF)

Class 1

No Physical Limitation
Medication

Class 4

Severe Physical Limitation
LVAD or Heart Transplant



Market Research



WHAT DOES THE MARKET NEED?

3 Main Requirements Emerged

1. Blood Pump Implant (>5 liters/min)
2. Catheter Procedure (no surgery)
3. Fully Implanted / Wirelessly powered
(no transdermal driveline)


Miniature Impeller Pump

- 8mm Pump Enables Catheter Delivery
- Tested Flow Rate = >6 liters / min
- Cover Article: August 2020 ASAIO Journal
- Patented Design



Intracardiac Implant

- Further enables transcatheter delivery
- Expands Indication:
Systolic AND Diastolic HF Patients
- Patented Design




Wireless Power Transmission

- Enables Fully Implanted Device
- Eliminates transdermal drivelines
- Patented Design

“All my LVAD patients would opt for another surgery to eliminate their driveline”

Leading Cardiologist, Hartford Hospital



Flushing and Maintenance System

- Enables safe positioning in bloodstream
- BiO-valve isolates pump from bloodstream
- Awarded NIH Grant (\$555k SBIR Phase 1 Grant)
- Patented Design



BiO-valve Open Position

"I believe your maintenance technology is truly unique"

Program Director, National Heart, Lung, and Blood Institute, NIH

CoRISMA Advantages

Competition

HeartMate 3 & Heartware



\$300k	Total Procedural Costs	\$150k
10 / 20 Days	Hospital Stay ICU/Total	2 / 4 Days
✗ 10-20%	Stroke Rate	✓ 1.7%*
✗ 20%	Power Line Infection	✓ 0%
✗ Low	Quality of Life	✓ High

“What you have is truly transformative”

Lead Cardiothoracic Surgeon, Stanford University School of Medicine

* Stroke rate anticipated to drop to average stroke rate of similar catheter procedures


Team : Experience, track record, and vision to succeed



Mike Theran
CEO, CoFounder



Jim Kelley
VP R&D



Colin Rolph
CFO



John Andres JD
IP Strategy



Nandini Murthy
VP Regulatory




Edward Berger
VP Reimbursement



Scott Wampler
VP Quality



Pramod Bonde MD
Chairman SAB, CoFounder



Vivek Reddy MD
Advisor




Srijoy Mahapatra MD
Advisor

Total Addressable Market without CoRISMA




Total Addressable Market with CoRISMA



"Heart Failure device market is fertile ground"

Former Chief Medical Officer Medtronic


Financial Projections



Rapid Adoption Anticipated

- Catheter procedures disrupt markets
- All Stakeholders are motivated
 - Patients
 - Clinicians
 - Hospitals
 - Insurance Companies
 - Governments

Financial Projections



Revenue Expected During Clinical

- Anticipate IDE Category B Designation*

* FDA Classification: Allow coverage of device during clinical study

Summary

ALL THE BOXES ARE CHECKED

✓	CoRISMA Drives Major Market Expansion
✓	Multiple Innovative, Patented, & Disruptive Features
✓	Strong and Experienced team

“CoRISMA has potential to be the most impactful cardiovascular device in decades”

Vivek Reddy MD, Mt Sinai Hospital New York

Contact Information

Mike Theran

Chief Executive Officer

CoRISMA Inc.

203-506-5025

www.linkedin.com/in/mike-theran

www.corismacv.com



Funding Rounds

Target Exit: Before Series C

